These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21092706)

  • 1. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.
    Doroud D; Vatanara A; Zahedifard F; Gholami E; Vahabpour R; Rouholamini Najafabadi A; Rafati S
    J Pharm Pharm Sci; 2010; 13(3):320-35. PubMed ID: 21092706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.
    Doroud D; Zahedifard F; Vatanara A; Taslimi Y; Vahabpour R; Torkashvand F; Vaziri B; Rouholamini Najafabadi A; Rafati S
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1236. PubMed ID: 21765963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.
    Doroud D; Vatanara A; Zahedifard F; Gholami E; Vahabpour R; Najafabadi AR; Rafati S
    J Control Release; 2010 Nov; 148(1):e105-6. PubMed ID: 21529578
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.
    Shahbazi M; Zahedifard F; Saljoughian N; Doroud D; Jamshidi S; Mahdavi N; Shirian S; Daneshbod Y; Hamid Zarkesh-Esfahani S; Papadopoulou B; Rafati S
    Vet Parasitol; 2015 Sep; 212(3-4):130-9. PubMed ID: 26255093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transfection with a novel cationic gene carrier: PEI-PBLG].
    Wei JZ; Lin L; Xiong W; Zhu QY
    Sheng Wu Gong Cheng Xue Bao; 2007 Mar; 23(2):229-34. PubMed ID: 17460893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Rafati S
    Parasite Immunol; 2011 Jun; 33(6):335-48. PubMed ID: 21410716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Taslimi Y; Vahabpour R; Torkashvand F; Vaziri B; Rafati S
    J Control Release; 2011 Jul; 153(2):154-62. PubMed ID: 21530597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
    Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
    PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems.
    Chen J; Tian B; Yin X; Zhang Y; Hu D; Hu Z; Liu M; Pan Y; Zhao J; Li H; Hou C; Wang J; Zhang Y
    J Biotechnol; 2007 Jun; 130(2):107-13. PubMed ID: 17467097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superparamagnetic nanoparticles for effective delivery of malaria DNA vaccine.
    Al-Deen FN; Ho J; Selomulya C; Ma C; Coppel R
    Langmuir; 2011 Apr; 27(7):3703-12. PubMed ID: 21361304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural investigation and intracellular trafficking of a novel multicomposite cationic solid lipid nanoparticle platform as a pDNA carrier.
    Vighi E; Leot E; Montanari M; Mucci A; Hanuskova M; Iannuccelli V
    Ther Deliv; 2011 Nov; 2(11):1419-35. PubMed ID: 22826874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfection of plasmid DNA by nanocarriers containing a gemini cationic lipid with an aromatic spacer or its monomeric counterpart.
    Martínez-Negro M; Barrán-Berdón AL; Aicart-Ramos C; Moyá ML; de Ilarduya CT; Aicart E; Junquera E
    Colloids Surf B Biointerfaces; 2018 Jan; 161():519-527. PubMed ID: 29128838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does the spacer length of cationic gemini lipids influence the lipoplex formation with plasmid DNA? Physicochemical and biochemical characterizations and their relevance in gene therapy.
    Muñoz-Úbeda M; Misra SK; Barrán-Berdón AL; Datta S; Aicart-Ramos C; Castro-Hartmann P; Kondaiah P; Junquera E; Bhattacharya S; Aicart E
    Biomacromolecules; 2012 Dec; 13(12):3926-37. PubMed ID: 23130552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low toxicity of cationic lipid-based emulsion for gene transfer.
    Choi WJ; Kim JK; Choi SH; Park JS; Ahn WS; Kim CK
    Biomaterials; 2004 Dec; 25(27):5893-903. PubMed ID: 15172502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspects of nonviral gene therapy: correlation of molecular parameters with lipoplex structure and transfection efficacy in pyridinium-based cationic lipids.
    Parvizi P; Jubeli E; Raju L; Khalique NA; Almeer A; Allam H; Manaa MA; Larsen H; Nicholson D; Pungente MD; Fyles TM
    Int J Pharm; 2014 Jan; 461(1-2):145-56. PubMed ID: 24296044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intracellular plasmid DNA localization of cationic reducible cholesterol-disulfide lipids.
    Sheng R; Luo T; Zhu Y; Li H; Sun J; Chen S; Sun W; Cao A
    Biomaterials; 2011 May; 32(13):3507-19. PubMed ID: 21329973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design flexibility influencing the in vitro behavior of cationic SLN as a nonviral gene vector.
    Vighi E; Montanari M; Hanuskova M; Iannuccelli V; Coppi G; Leo E
    Int J Pharm; 2013 Jan; 440(2):161-9. PubMed ID: 22982257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
    Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.